Physician profile
Julia Kaplun
NPI 1306809181
$5,891.02
in general payments reported to CMS, 2019-2025
35 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $625 · 2021: $368 · 2022: $1,032 · 2023: $1,144 · 2024: $1,139 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,440.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,193.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $564.10 | 2019-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $529.61 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Tandem Diabetes Care, INC. | $500.00 | 2020 | |
| Corcept Therapeutics | $294.01 | 2021-2025 | Korlym |
| Mannkind Corporation | $288.78 | 2019-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $264.47 | 2023-2025 | |
| Abbvie INC. | $241.33 | 2021-2025 | |
| Dexcom, INC. | $229.11 | 2020-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $225.56 | 2019-2025 | Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $158.76 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $139.04 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.69 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $113.55 | 2024-2025 | Recorlev |
| Insulet Corporation | $101.95 | 2019-2025 | Omnipod |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $99.94 | 2024-2025 | |
| Embecta Corp. | $92.09 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Antares Pharma, INC. | $82.34 | 2024-2025 | Xyosted |
| Radius Health, INC. | $79.09 | 2021-2025 | Tymlos |
| Ibsa Pharma INC. | $76.46 | 2020-2024 | Licart, Tirosint |
| Glaxosmithkline, LLC. | $75.09 | 2023-2024 | Arexvy, Shingrix |
| Amneal Pharmaceuticals LLC | $53.83 | 2020-2024 | Unithroid |
| Madrigal Pharmaceuticals | $47.88 | 2025 | Rezdiffra |
| Becton, Dickinson and Company | $38.52 | 2022 | |
| Chiesi USA, INC. | $36.10 | 2024-2025 | Mycapssa |
| Horizon Therapeutics Plc | $35.46 | 2022-2023 | Tepezza |
| Medtronic, INC. | $32.41 | 2023-2024 | Minimed 780g |
| Azurity Pharmaceuticals, INC. | $31.88 | 2023 | Adthyza |
| Neurocrine Biosciences, INC. | $31.53 | 2025 | |
| Sandoz INC. | $27.44 | 2025 | Jubbonti |
| Merck Sharp & Dohme LLC | $26.78 | 2019-2022 | |
| Rgh Enterprises LLC | $17.30 | 2024 | |
| Halozyme INC | $15.16 | 2023 | |
| Shire North American Group INC | $12.74 | 2019 | |
| Valeritas, INC. | $12.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Kaplun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.